Following a ~7% rise in the previous session, AnaptysBio (NASDAQ:ANAB) extended gains in the premarket on Wednesday after the ...

AnaptysBio Inc.’s shares rose to a six-month high on Tuesday following the announcement of successful Phase 2b results from ...

A large-scale study reveals that rheumatoid arthritis patients—especially those seropositive or on DMARD therapy—face ...

In February 2025, A naptysBio announced promising results from a global Phase IIb trial (RENOIR) for rosnilimab, a novel ...

The spring meeting of the Irish Society for Rheumatology brought together experts from across Ireland and the UK to highlight ...

Symptoms of early arthritis can be easy to overlook, but seeking prompt treatment can help you manage discomfort and protect ...

Women with rheumatoid arthritis have a longer disease duration before being prescribed disease-modifying antirheumatic drugs ...

A commonly used arthritis medication failed to improve symptoms in people with a specific form of knee osteoarthritis, according to an article published June 2 in JAMA Internal Medicine. In a ...

The first systematic genome-wide association study for pseudogout has identified two genes strongly associated with disease ...

Rheumatoid arthritis is less common than osteoarthritis, affecting around 514,000 Australians. It mostly impacts the wrists and small joints in the hands and feet, though larger joints such as the ...

Biosimilars offer high-quality, lower-cost cancer treatments. Learn how they’re helping patients and reshaping global ...